Regen BioPharma Inc (RGBP)

[SidVicious]

Details of the the collaborative deal between Regen and NCATS for those who actually want to know the facts of what each is bringing to the deal (hint, no money is being given to REGEN contrary to the misinformation being posted on here):

full text here:

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11065814


aPPeNDIX a
research Project Summary
I. abstract of the research Project – for Public release
EITHER PARTy mAy, wITHOuT FuRTHER CONSuLTATION OR PERmISSION, RELEASE THIS ABSTRACT TO THE PuBLIC. Project Title: Identification of possible ligands for the NR2F6 orphan nuclear receptor.
Project Abstract: These studies are designed to screen for small molecule compounds that activate or inhibit the orphan nuclear receptor, NR2F6. Small molecule
compounds from the NCATs compound libraries will be screened against cell lines expressing either the ligand binding domain or the full length protein of NR2F6
fused to a luciferase-based reporter construct and stably expressed in HEK293 cells.

II. goal(s) of Project: To identify possible ligands for the NR2F6 orphan nuclear receptor by screening the reporter gene assay of NR2F6 cell lines using known
compound libraries, NPC and LOPAC. Such ligands that show specificity for NR2F6 may lead to the development of novel immunotherapy treatments.

III. background: The immunotherapy of cancer has completely changed the clinical management of various tumors and has dramatically improved the survival
rates in those people with melanoma and lymphoma. The key discovery of this field was the identification of immune checkpoints – molecules whose expression
leads to the shutting down of the immune system’s natural ability to kill cancerous cells. There are currently three checkpoint proteins that have been identified and
for which there are now clinically useful drugs which target these. All of these proteins are expressed as cell surface proteins and the treatments involve injection
of antibodies to these proteins.
Regen has identified a nuclear receptor, NR2F6, which has properties very much like the known checkpoint proteins. So far, the only ways to inhibit this receptor
include the use of gene silencing techniques or knock outs in mice. Identification of a small molecule which could inhibit this receptor would potentially provide a
major new avenue for immunotherapy of cancer.

IV. respective Contributions of the Parties
material Contributed by NCatS: NPC and LOPAC compound libraries will be used to screen this receptor at NCATS.
material  Contributed  by  Collaborator  : NR2F6 orphan nuclear receptor cell lines will be provided by Regen. These lines will be HEK293 lines stably
expressing NR2F6 ligand binding domain or the full-length NR2F6 protein as well as a positive control line expressing the estrogen receptor. Each of these target
nuclear receptors will be fused to a luciferase-based reporter gene assay vector.

V. experimental Plan: Cell lines (LBD, Full-length and positive control ER) will be transferred onto screening robotic system. Compound